PUBLIC COMPANY
save$TARAProtara Therapeutics, Inc.
$TARANew York, NY, USupdated 18d ago
community read0 votes
pipeline
2
marketed
0
phase 3
1
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(2)
pipeline depth2 products
1Phase 21Phase 3
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase2Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer
- phase3Study of Choline Chloride for Injection in Adolescent and Adult Patients With Intestinal Failure Receiving Long Term Parenteral Support
- phase3Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder Cancer
- phase2Safety and Efficacy Study of Intracystic TARA-002 for the Treatment of Lymphatic Malformations in Participants 6 Months to Less Than 18 Years of Age
- phase1Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults with High-grade Non-muscle Invasive Bladder Cancer (Phase 1b)
- phase1Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults with High-grade Non-muscle Invasive Bladder Cancer (Phase 1a)
- —Prevalence of Liver Disease in Patients Dependent on Parenteral Nutrition
Insider activity
source: SEC Form 4🐶 Hiring Signal
News
- Everything the Trump administration did on health care last weekAn executive order remaking the federal vaccine agenda, Epic's antitrust lawsuits, and more health news from Morning Roundsstat · 14h ago
- STAT+: State laws may be curbing private equity takeovers of physician groupPrivate equity deals for practice management firms are declining sharply.stat · 22h ago
- STAT+: Providers notch No Surprises Act legal win that could boost their payThe change could boost how much health insurers, and patients, pay for some care.stat · 5d ago
- STAT+: Elevance plots a Medicaid retreat as costs remain highElevance Health, the country’s second-biggest health insurer, said it plans to further shrink its Medicaid portfolio in the coming year, just as states roll out work requirements.stat · 1mo ago
- What to know about the parasitic diarrhea outbreakFallout from the end of ACA subsidies, the FDA CBER acting director "on planet Earth," and more health news from Morning Roundsstat · 1mo ago
- STAT+: Hospital chain HCA warns of lower profits as more patients go uninsuredIt's an early indicator of the fallout from the end of extra ACA subsidies.stat · 1mo ago
- Caregivers brace for pay cuts, and maybe homelessnessA game-changer in pancreatic cancer, a vaccine skeptical HHS nom, and more health news from Morning Roundsstat · 1mo ago
- STAT+: Medicare takes another swing at 340B cuts to hospitalsReducing Medicare payments for 340B drugs is the latest proposal focused on the hotly debated drug discount program.stat · 1mo ago
- 5 takeaways from STAT’s investigation into microhospital operator Nutex HealthRead the takeaways from STAT's investigation into Nutex, which used the No Surprises Act to fuel a stunning financial turnaround.stat · 1mo ago
- STAT+: Eli Lilly ends 340B drug discounts to some hospitals for failing to provide claims dataMaking good on its threat, Eli Lilly has begun eliminating mandated price breaks to a few dozen hospitals that participate in a federal drug discount program.stat · 2mo ago
Data sources
last refreshed 4m ago
Found something off?
comments(0)
5-min edit window · permanent after that